Sentence examples for multiple tumour cell from inspiring English sources

Several top candidates were converted to IgG1 and further characterised for agonist activity on multiple tumour cell types and antitumour activity in xenograft models.

For α7β1 integrin, the relatively limited data available indicate that it plays a tumour-suppressive role in multiple tumour cell types (Ref. 52).

Indeed, antiproliferative effects of metformin have been reported in multiple tumour cell lines via several molecular pathways, including the adenosine monophosphate kinase (AMPK) pathway, the insulin receptor cascade, and the AMPK-independent RagGTPase-dependent 3mTORC1 signalling network [ 1, 3].

This selective lytic effect on cancer has been demonstrated in vitro in multiple tumour cell types, and has been extended to in vivo animal models (Koga et al, 2001; Komata et al, 2001; Gu et al, 2002).

HGS-ETR1 induction of cell killing and mechanism of action were analysed in multiple tumour cell lines (SW480, Colo205, HCT116, H2122, H460, SU.86.86, RL95-2, ST486, JURL-MK1, A498, SNU398, and WM793), representing various tumour types (Table 1).

We describe a new method for the isolation of single tumour cells and completely purified groups of multiple tumour cells from immunomagnetically pre-enriched blood samples using two different sample preparation workflows.

Human IFN- β can be used to inhibit the proliferation of multiple tumour cells for the potent antiangiogenic and antimetastatic effect (Zhang et al, 2002; Angelucci et al, 2007; Ren et al, 2008).

Overexpression of bcl-2 in multiple tumour cells increases radiation resistance (Gasparini et al, 1995; Weller et al, 1995; Mackey et al, 1998), and bax, the other number of the bcl-2 family, antagonises the bcl-2 function by forming a heterodimer.

In a panel of multiple solid tumour cell lines, XL844 had little effect as a single agent, but substantially increased the cytotoxicity of gemcitabine (Matthews et al, 2007).

Targeting SMOH through lentivector-mediated short hairpin RNA (shRNA) silencing mimics the effects of cyclopamine in multiple human tumour cells (Clement et al, 2007; Stecca et al, 2007; Varnat et al, 2009).

The relative increased expression of INSR (a receptor for insulin) and IGF1 in the resistant cohort in our study indicates that the drug resistant cells evolve multiple compensatory mechanisms for tumour cell survival.